MedTrace Logo

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

NCT05777031 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-03-23

No results posted yet for this study

Summary

The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.

Conditions

  • Peyronie Disease
  • Sexual Dysfunctions, Psychological
  • Genital Diseases, Male

Interventions

DRUG

Collagenase Clostridium Histolyticum (CCH)

Injection of intralesional CCH (0.58mg) to the penile plaque at the point of maximal curvature. Second injection of each cycle will be injected 2-3mm apart from the prior injection.

Sponsors & Collaborators

  • Endo Pharmaceuticals

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Thomas Masterson, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2027-01-15
Completion
2027-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05777031 on ClinicalTrials.gov